
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter A - General
#### PART 54 - FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS
##### ยง 54.5 Agency evaluation of financial interests.
###### Evaluation of disclosure statement.

(a)FDA will evaluate the information disclosed under ยง 54.4(a)(2) about each covered clinical study in an application to determine the impact of any disclosed financial interests on the reliability of the study. FDA may consider both the size and nature of a disclosed financial interest (including the potential increase in the value of the interest if the product is approved) and steps that have been taken to minimize the potential for bias.
